A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

November 9, 2018

Study Completion Date

November 9, 2018

Conditions
Stable Coronary Heart Disease
Interventions
DRUG

MEDI5884

Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.

DRUG

Placebo

Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.

Trial Locations (23)

31406

Research Site, Savannah

32003

Research Site, Fleming Island

32127

Research Site, Port Orange

32216

Research Site, Jacksonville

33024

Research Site, Pembroke Pines

35801

Research Site, Huntsville

36207

Research Site, Anniston

37660

Research Site, Kingsport

40213

Research Site, Louisville

43302

Research Site, Marion

44224

Research Site, Stow

45219

Research Site, Cincinnati

46260

Research Site, Indianapolis

57701

Research Site, Rapid City

58103

Research Site, Fargo

60201

Research Site, Evanston

73134

Research Site, Oklahoma City

78228

Research Site, San Antonio

78503

Research Site, McAllen

91325

Research Site, Northridge

92020

Research Site, El Cajon

95648

Research Site, Lincoln

06708

Research Site, Waterbury

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY